Crinetics Showcases the Next Generation of Endocrinology Innovation at ENDO 2025


“ENDO 2025 will be an incredibly meaningful moment for Crinetics and our mission to be the premier endocrine-focused global pharmaceutical company.”

– Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics

Read our full ENDO 2025 Press Release
scott struthers ceo uai

PALSONIFY™ (paltusotine) Presentations:

Author: David Clemmons, MD et. al.
Date/Time: July 13, 12:00–1:30 PM

Atumelnant Presentations:

Early Pipeline Presentations:

Science & Innovation Theaters


Optimizing Long-Term Control in Acromegaly: Key to Improved Patient Outcomes
Presenters: Shlomo Melmed, MB ChB; Christian J. Strasburger, MD
Date/Time: July 14, 9:30 AM-10:30 AM

Navigating the Complexities & Challenges of Acromegaly Management
Presenters: Lisa B. Nachtigall, MD; Laurence Katznelson, MD; Stephen Betz, Ph.D.
Date/Time: July 14, 12:30 PM -1:30 PM

Attending ENDO 2025?

Stop by booth 509 to meet our team in person

crinetics lab pablo uai

Exploring new frontiers with our science to expand patient reach

Our in-house R&D team of proven drug hunters develops transformative novel molecules with a focus on the endocrine system and G-protein coupled receptors. Our pipeline is purposefully created to deliver innovative therapies.

SEE OUR PIPELINE ➡

Live from ENDO 2025


Connect With Us


For Healthcare Professionals only: Use the form below to submit a general Medical Inquiry.

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.